Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 13/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010191 | 0.86 | PDK1 (0.50) | MGLLFAAHGPR119 | |
| SCHEMBL2002657 | 0.79 | MLNR (0.36) | — | |
| SCHEMBL2005928 | 0.79 | KCNK3 (0.33) | MGLLGPR119ENPP2 | |
| SCHEMBL3664002 | 0.74 | MGLL (0.49) | MGLLGPR119PTGDR2 | |
| SCHEMBL3664004 | 0.74 | MGLL (0.49) | MGLLGPR119PTGDR2 | |
| SCHEMBL7968974 | 0.74 | MGLL (0.49) | MGLLGPR119PTGDR2 | |
| SCHEMBL3135296 | 0.72 | CCR1 (0.41) | MGLLFAAHPTGDR2 | |
| SCHEMBL1632054 | 0.72 | FAAH (0.44) | MGLLFAAHGPR119MAP4K4 | |
| SCHEMBL28388288 | 0.72 | CCR1 (0.45) | MGLLGPR119PTGDR2MAP4K4ENPP2 | |
| SCHEMBL28388289 | 0.72 | CCR1 (0.45) | MGLLGPR119PTGDR2MAP4K4ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | MGLL 398/4885FAAH 460/4885GPR119 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.